000891737 000__ 04501cam\a2200457Ii\4500
000891737 001__ 891737
000891737 005__ 20230306150218.0
000891737 006__ m\\\\\o\\d\\\\\\\\
000891737 007__ cr\cn\nnnunnun
000891737 008__ 190702t20192019sz\\\\\\ob\\\\001\0\eng\d
000891737 020__ $$a9783030182182$$q(electronic book)
000891737 020__ $$a3030182185$$q(electronic book)
000891737 020__ $$z9783030182175
000891737 035__ $$aSP(OCoLC)on1107041906
000891737 035__ $$aSP(OCoLC)1107041906
000891737 040__ $$aN$T$$beng$$erda$$epn$$cN$T$$dN$T$$dEBLCP$$dUKMGB
000891737 049__ $$aISEA
000891737 050_4 $$aRC802
000891737 08204 $$a616.33$$223
000891737 24500 $$aUsing central neuromodulators and psychological therapies to manage patients with disorders of gut-brain interaction :$$ba clinical guide /$$ceditor, W. Harley Sobin.
000891737 264_1 $$aCham, Switzerland :$$bSpringer,$$c[2019]
000891737 264_4 $$c©2019
000891737 300__ $$a1 online resource.
000891737 336__ $$atext$$btxt$$2rdacontent
000891737 337__ $$acomputer$$bc$$2rdamedia
000891737 338__ $$aonline resource$$bcr$$2rdacarrier
000891737 504__ $$aIncludes bibliographical references and index.
000891737 5050_ $$aIntro; Foreword; Disorders of Gut-Brain Interaction: A Coming of Age for the Clinician; Preface; Contents; Contributors; Chapter 1: The Gut-Brain Connection and Its Significance to Gastroenterologists; References; Chapter 2: How to Use Central Neuromodulators (CNs) to Help Manage Patients with Disorders of Gut-Brain Interaction (DGBI); When to Start Central Neuromodulators (CNs); The Monoamine Hypothesis; SSRIs, SNRIs, and TCAs; SSRIs; SNRIs; TCAs; Action of CNs on Various Receptors; Mirtazapine; Buspirone; Trazodone; Atypical Antipsychotics
000891737 5058_ $$aOn Choosing a Neuromodulator for a Specific SymptomFunctional Dyspepsia-EPS Type; Functional Dyspepsia-PDS Type; Nausea and Vomiting; Cyclic Vomiting Syndrome; Side Effects of Central Neuromodulators; Questions That Are Frequently Asked; Pitfalls in Management; References; Chapter 3: A Psychopharmacology Guide by Psychiatrists for Non-psychiatrists; Introduction; Principles of Psychopharmacology; Diagnosis and Symptom Assessment; Selecting a Psychopharmacology Treatment; Drug-Drug Interactions; Treatment Course; General Comments on Discontinuation; Antidepressants; Initiating; Monitoring
000891737 5058_ $$aDiscontinuingFirst-Generation Antidepressants; Monoamine Oxidase Inhibitors; Tricyclic Antidepressants; Second-Generation Antidepressants; Selective Serotonin Reuptake Inhibitors; Serotonin and Norepinephrine Reuptake Inhibitors; Atypical Antidepressants; Serotonin Modulators; Benzodiazepines and Related Sedatives; Benzodiazepines; Adverse Effects; Discontinuation; Nonbenzodiazepine Hypnotics; Adverse Effects; Buspirone; Adverse Effects; Antipsychotics; Initiating; Monitoring; Discontinuing; First-Generation Antipsychotics (FGAs); Second-Generation Antipsychotics (SGAs)
000891737 5058_ $$aExtrapyramidal Symptoms and Neuroleptic Malignant SyndromeMood Stabilizers; Initiating; Monitoring; Discontinuing; Lithium; Antiepileptics; Valproate; Carbamazepine; Lamotrigine; Psychopharmacology in the Medically Ill; Renal; Cardiovascular; Endocrine; References; Chapter 4: Discussion on the Use of Psychiatric Medications: Questions by W. Harley Sobin MD Answers by Thomas W. Heinrich MD; Chapter 5: Cognitive-Behavioral Therapy for Irritable Bowel Syndrome; Case 1: Shelly; Session 1; Session 2; Session 3; Session 4; Session 5; Session 6; Session 7; Session 8; Case 2: Tom; Session 1
000891737 5058_ $$aSession 2Session 3; Session 4; Session 5; Session 6; Session 7; Session 8; Summary; References; Chapter 6: Exposure Therapy for Functional GI Disorders; The Nature of Anxiety; The Role of Negative Reinforcement; Exposure Therapy with Response Prevention Applied to Functional GI Disorders; Exposure Therapy for a Patient Disabled by Belly Pain; Beginning Treatment: Explain to Your Patient the Following Information; Defining Targets for Exposure; Making Exposure Therapy Successful; Exposure to Worry; Exposure to Uncertainty; Length of Treatment; Avoiding Being the Negative Reinforcer; Summary
000891737 506__ $$aAccess limited to authorized users.
000891737 588__ $$aOnline resource; title from PDF title page (viewed July 5, 2019).
000891737 650_0 $$aGastrointestinal system$$xDiseases$$xPsychosomatic aspects.
000891737 650_0 $$aDigestive organs$$xDiseases$$xPsychological aspects.
000891737 7001_ $$aSobin, W. Harley,$$eeditor.
000891737 852__ $$bebk
000891737 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-3-030-18218-2$$zOnline Access$$91397441.1
000891737 909CO $$ooai:library.usi.edu:891737$$pGLOBAL_SET
000891737 980__ $$aEBOOK
000891737 980__ $$aBIB
000891737 982__ $$aEbook
000891737 983__ $$aOnline
000891737 994__ $$a92$$bISE